Report to the Budapest Stock Exchange 6 months to June 2021 +
The shares owned by the Hungarian State and held by the Hungarian State Holding Company (MNV Zrt) declined to 5 25 percent as the Hungarian State conceded a 10 percent stake to the Tihanyi Foundation +
Report to the Budapest Stock Exchange 12 months to December 2020 +
+
Report to the Budapest Stock Exchange 9 months to September 2020 +
Report to the Budapest Stock Exchange 6 months to June 2020 +
Report to the Budapest Stock Exchange 3 months to March 2020 +
Myovant Sciences and Gedeon Richter Plc. today announced that they have entered into an exclusive license agreement for Gedeon Richter to commercialize relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for uterine fibroids and endometriosis in Europe, the Commonwealth of Independent States including Russia, Latin America, Australia, and New Zealand. +
Gedeon Richter Plc. today announced that the European Medicines Agency (EMA) has accepted Richter’s regulatory submission for a combined oral contraceptive, containing estetrol (E4) and drospirenone. +
Report to the Budapest Stock Exchange 12 months to December 2019 +
Consolidated sales at HUF 369,059 million, EUR 1,142.8 million, increased by HUF 45,184 million or 14.0% (by EUR 121.9 million or 11.9%) during the first nine months to September 2019 when compared with the same period in 2018. +
Consolidated sales at HUF 445,484 million, EUR 1,398.2 million, remained virtually flat during 2018, (increased by HUF 1,128 million or 0.3%) and decreased by EUR 38.6 million (2.7%) when compared with 2017. +
Consolidated sales at HUF 323,875 million, EUR 1,020.9 million, declined in the first nine months 2018 by HUF 10,278 million (3.1%) and by EUR 62.3 million (5.8%) when compared with the same period 2017. +
Consolidated sales at HUF 224,430 million, EUR 713.9 million, declined in the first half 2018 by HUF 2,359 million (1.0%) and by EUR 19.0 million (2.6%) when compared with the same period 2017. +
Gedeon Richter Plc. today announced that it has entered into an exclusive license and distribution agreement with Prima-Temp Inc., a US, Colorado based company, to commercialize its innovative medical device, PriyaRing globally, except for the USA and Canada. PriyaRing is an internal sensor that identifies the subtle temperature changes that occur prior to ovulation. +
Gedeon Richter Plc. announces that the European Commission has granted marketing authorization to Reagila® (cariprazine) a novel antipsychotic for the treatment of schizophrenia in adult patients. +
Gedeon Richter Plc. announces that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has adopted a positive opinion on the company’s application for cariprazine, a novel antipsychotic for the treatment of schizophrenia in adult patients. +
Sales in 2016 increased by 6.7% in HUF and by 6.1% in EUR terms when compared to 2015. +
Gedeon Richter Plc. announced that it has entered into a distribution and supply agreement with Allergan to commercialize its levonorgestrel releasing Intrauterine System (IUS) in Western Europe and in other European countries under the trademark of Levosert® +
- First oral therapy to demonstrate efficacy and safety for uterine fibroids in two U.S. pivotal studies - VENUS II study reinforces efficacy, safety seen in VENUS I study, meeting all co-primary and secondary endpoints +
Gedeon Richter Plc. (“Richter”) today announced that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending that marketing authorization be granted for its biosimilar teriparatide, Terrosa. +
Richter Group Report - Q3 2016 +
Gedeon Richter Plc. anunciou hoje que assinou a transferência de tecnologia e contrato de licenciamento com a DM Bio ("DM Bio") no que respeita ao desenvolvimento e comercialização de anticorpo monoclonal biosimilar, Trastuzumab. +
Gedeon Richter Plc ("Richter")announces the acquisition of Finox Holding ("Finox"), a privately held Swiss biotech company focused on development and commercialisation of innovative and cost effective products addressing female fertility. +
Phase III study met all co-primary and secondary endpoints and achieved statistically significant results. Allergan Plc and Gedeon Richter Plc. today announced positive results from Venus I, one of two pivotal Phase III clinical trials evaluating the efficacy and safety of ulipristal acetate... +
Market capitalisation on 31 December 2015 in Euro terms was EUR 3.3 billion, about 56 percent above the EUR 2.1 billion recorded on 31 December 2014. +
Gedeon Richter Plc. (“Richter”) today announced that the European Medicines Agency (EMA) has accepted Richter’s regulatory submission for cariprazine, a novel antipsychotic for the treatment of schizophrenia in adult patients. +
Gedeon Richter Plc. (“Richter”) today announced that the European Medicines Agency (EMA) has accepted Richter’s regulatory submission for its proposed biosimilar to Amgen’s Neulasta (pegfilgrastim). +
Gedeon Richter Interim Report H1 2015 +
This decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on 23 April 2015 and is applicable for all Member States in the European Economic Area. +
Gedeon Richter Plc. announces that the CHMP of the EMA has adopted a positive opinion on the company’s application to extend the indication of Esmya® 5 mg tablets (ulipristal acetate) to the long term repeated intermittent treatment of moderate to severe symptoms of uterine fibroids. +
Gedeon Richter Plc. anunciou hoje que assinou um contrato de licenciamento e de distribuição com a Bayer HealthCare para comercializar na União Europeia, outros países da Europa e na América Latina, um contracetivo transdérmico semanal de baixa dosagem contendo Gestodeno + Etinilestradiol, +
Gedeon Richter Plc. today announced positive top-line results from a Phase IIIb trial evaluating the efficacy, safety and tolerability of cariprazine, a new atypical antipsychotic, in adult schizophrenia patients with persistent and predominant negative symptoms. +
Gedeon Richter Plc. and Actavis plc (NYSE: ACT) today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. +
US biopharma company Palatin Technologies says it has started its bremelanotide pivotal registration… +
Gedeon Richter Plc. and Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission. +
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide... +
O livro “Albino Aroso - um homem à frente do seu tempo” foi apresentado no passado dia 04 Novembro, na Sede da Secção Norte da Ordem dos Médicos, com o objectivo de lembrar o propulsor das consultas de Planeamento Familiar em Portugal. +
A Direcção de Internato Médico do Serviço de Saúde da Região (SESARAM) promove nos próximos dias 14 e 15 de Novembro, no Colégio dos Jesuítas (Reitoria da Universidade da Madeira) as VI Jornadas do Médico Interno da RAM. +
Começou na semana passada a recolha de dados junto das mulheres sobre "Avaliação das práticas contraceptivas das mulheres em Portugal", o maior estudo nacional na área da contracepção, que pretende analisar os hábitos contraceptivos da população feminina do país entre os 15 e os 49 anos. +
Começa hoje a recolha de dados junto das mulheres sobre "Avaliação das práticas contraceptivas das mulheres em Portugal", o maior estudo nacional na área da contracepção, que pretende analisar os hábitos contraceptivos da população feminina do país entre os 15 e os 49 anos. +
Palatin Technologies, Inc. (NYSE MKT: PTN; hereinafter: "Palatin") and Gedeon Richter Plc. (hereinafter: "Richter") announced that they have entered into a collaboration and license agreement, to co-develop and commercialize bremelanotide for female sexual dysfunction (FSD)... +
Gedeon Richter Plc. and Forest Laboratories, Inc. (NYSE: FRX) announced positive topline results from a Phase IIb trial evaluating the efficacy and safety of the investigational antipsychotic cariprazine in patients with bipolar depression. +